StockSelector.com
  Research, Select, & Monitor Wednesday, April 25, 2018 12:32:03 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Aclaris Therapeutics, Inc.$17.68($.09)(.51%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Aclaris Therapeutics, Inc. has an overall rank of 4796 out of 6923 stocks based on 7 positive rankings and 7 negative rankings.

Positive Rankings
Estimated Revenue Growth
Aclaris Therapeutics rank is 10
Target Prices
The average analysts' target price is $52.50 for Aclaris Therapeutics using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Aclaris Therapeutics is ranked 43.
Debt-to-Equity
Aclaris Therapeutics rank is 127
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Aclaris Therapeutics is ranked 306.
10 Day Gain
Aclaris Therapeutics rank is 1275
Up EPS Surprise
Aclaris Therapeutics beat the consensus earnings estimate when it last reported quarterly earnings.
Low Put/Call
Aclaris Therapeutics has a low Put/Call ratio of 0.55 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Aclaris Therapeutics is ranked 1413.
Negative Rankings
Price-to-Sales
Aclaris Therapeutics rank is 57
Negative Net Margin
Aclaris Therapeutics rank is 86
90 Day Loss
Aclaris Therapeutics rank is 421
High vPut/Call
Aclaris Therapeutics has a high Put/Call ratio of 2.35 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Aclaris Therapeutics is ranked 461.
Negative ROA
Aclaris Therapeutics rank is 742
Negative ROE
Aclaris Therapeutics rank is 765
Price-to-Book
Aclaris Therapeutics rank is 2008







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.